These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
473 related articles for article (PubMed ID: 19667211)
1. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Cepok S; Schreiber H; Hoffmann S; Zhou D; Neuhaus O; von Geldern G; Hochgesand S; Nessler S; Rothhammer V; Lang M; Hartung HP; Hemmer B Arch Neurol; 2009 Oct; 66(10):1216-23. PubMed ID: 19667211 [TBL] [Abstract][Full Text] [Related]
2. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis. Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161 [TBL] [Abstract][Full Text] [Related]
3. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S; Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883 [TBL] [Abstract][Full Text] [Related]
4. Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system. Shapiro AM; Jack CS; Lapierre Y; Arbour N; Bar-Or A; Antel JP Arch Neurol; 2006 Sep; 63(9):1296-9. PubMed ID: 16966508 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta. Sominanda A; Lundkvist M; Fogdell-Hahn A; Hemmer B; Hartung HP; Hillert J; Menge T; Kieseier BC Arch Neurol; 2010 Sep; 67(9):1095-101. PubMed ID: 20837854 [TBL] [Abstract][Full Text] [Related]
6. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Hesse D; Sellebjerg F; Sorensen PS Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141 [TBL] [Abstract][Full Text] [Related]
7. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Sorensen PS; Koch-Henriksen N; Ross C; Clemmesen KM; Bendtzen K; Neurology; 2005 Jul; 65(1):33-9. PubMed ID: 15888603 [TBL] [Abstract][Full Text] [Related]
8. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis. Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450 [TBL] [Abstract][Full Text] [Related]
9. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Krumbholz M; Theil D; Cepok S; Hemmer B; Kivisäkk P; Ransohoff RM; Hofbauer M; Farina C; Derfuss T; Hartle C; Newcombe J; Hohlfeld R; Meinl E Brain; 2006 Jan; 129(Pt 1):200-11. PubMed ID: 16280350 [TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Bilgic H; Ytterberg SR; Amin S; McNallan KT; Wilson JC; Koeuth T; Ellingson S; Newman B; Bauer JW; Peterson EJ; Baechler EC; Reed AM Arthritis Rheum; 2009 Nov; 60(11):3436-46. PubMed ID: 19877033 [TBL] [Abstract][Full Text] [Related]
12. Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. Buttmann M; Merzyn C; Rieckmann P J Neuroimmunol; 2004 Nov; 156(1-2):195-203. PubMed ID: 15465611 [TBL] [Abstract][Full Text] [Related]
13. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort. McKay F; Schibeci S; Heard R; Stewart G; Booth D J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664 [TBL] [Abstract][Full Text] [Related]
14. [Correlation of chemokines and chemokine receptors with clinical features in newly diagnosed systemic lupus erythematosus]. Tao JH; Li XP; Li XM; Kan M; Zhai ZM; Wang W Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3051-4. PubMed ID: 17288835 [TBL] [Abstract][Full Text] [Related]
15. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies? Sorensen PS; Koch-Henriksen N; Flachs EM; Bendtzen K Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772 [TBL] [Abstract][Full Text] [Related]
16. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. Santos R; Weinstock-Guttman B; Tamaño-Blanco M; Badgett D; Zivadinov R; Justinger T; Munschauer F; Ramanathan M J Neuroimmunol; 2006 Jul; 176(1-2):125-33. PubMed ID: 16698090 [TBL] [Abstract][Full Text] [Related]
17. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis]. Seres E; Vécsei L Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710 [TBL] [Abstract][Full Text] [Related]
18. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice. Farrell RA; Espasandin M; Lakdawala N; Creeke PI; Worthington V; Giovannoni G Mult Scler; 2011 Nov; 17(11):1333-40. PubMed ID: 21685230 [TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. Hong J; Zang YC; Hutton G; Rivera VM; Zhang JZ J Neuroimmunol; 2004 Jul; 152(1-2):126-39. PubMed ID: 15223245 [TBL] [Abstract][Full Text] [Related]
20. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]